HC Wainwright reiterated their buy rating on shares of Vivani Medical (NASDAQ:VANI - Free Report) in a research note issued to investors on Wednesday,Benzinga reports. The firm currently has a $4.00 price target on the stock.
Vivani Medical Price Performance
Vivani Medical stock traded down $0.04 during mid-day trading on Wednesday, reaching $1.11. 186,001 shares of the company traded hands, compared to its average volume of 174,811. Vivani Medical has a 52-week low of $1.03 and a 52-week high of $2.22. The firm has a market capitalization of $65.75 million, a price-to-earnings ratio of -2.47 and a beta of 3.20. The firm's 50 day moving average price is $1.14 and its 200 day moving average price is $1.21.
Institutional Trading of Vivani Medical
Several large investors have recently bought and sold shares of the company. Geode Capital Management LLC boosted its holdings in shares of Vivani Medical by 4.6% during the 3rd quarter. Geode Capital Management LLC now owns 342,891 shares of the company's stock valued at $401,000 after buying an additional 15,008 shares in the last quarter. Northern Trust Corp boosted its position in shares of Vivani Medical by 19.1% during the fourth quarter. Northern Trust Corp now owns 71,915 shares of the company's stock valued at $83,000 after buying an additional 11,540 shares during the last quarter. Jane Street Group LLC bought a new stake in Vivani Medical in the 4th quarter worth about $66,000. Finally, Wealthedge Investment Advisors LLC purchased a new position in Vivani Medical in the 4th quarter worth about $43,000. 6.78% of the stock is owned by institutional investors.
Vivani Medical Company Profile
(
Get Free Report)
Vivani Medical, Inc, a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals.
Recommended Stories
Before you consider Vivani Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vivani Medical wasn't on the list.
While Vivani Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
